Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 8 of 8 for “"Ticagrelor"”.
-
Downstream Cangrelor versus upstream ticagrelor in patients with St-Segment elevation myocardial infarction
… (ovvero, “downstream”) con il pretrattamento con ticagrelor (ovvero, “upstream”). Metodi: Sono stati inclusi pazienti con STEMI sottoposti a PCI tra ottobre 2019 e giugno 2023. L’endpoint primario era l’insieme degli eventi avversi cardiovascolari maggiori (MACE) durante il ricovero. Gli endpoint …
-
Improving outcomes in patients with coronary heart disease using national registers and platelet function testing
… 5 different anti-platelet protocols, ticagrelor pre-treatment and treatment delays to PCI). Two papers involved evaluation of interventions: platelet function testing in patients with clopidogrel and clinical evaluation of bivalirudin versus heparin in patients with acute coronary …
-
Aspects of bleeding complications and hemostasis at central line insertion and mild induced hypothermia
… with dual platelet inhibition, including ticagrelor and aspirin, this effect was offset by powerful P2Y12 blockade, confirmed by analysis of vasodilator-stimulated phosphoprotein. The effect of ticagrelor was delayed in survivors of cardiac arrest, probably due to slow gastric emptying. …
-
Genotype- versus phenotype-directed personalization of antiplatelet treatment in Koreans with coronary artery disease undergoing coronary stenting
… of P2Y12 reaction unit (PRU), were given 90 mg ticagrelor twice daily; non-carriers or patients without HOPR were given 75 mg clopidogrel daily. The primary endpoint was the percentage of patients with HOPR after 30 days of treatment. PRU decreased following both genotype- and phenotype-directed …
-
Novel Agonists and Antagonists of Platelet Receptors
… of the antiplatelet substances, clopidogrel and ticagrelor (AZD6140) a reversibly non-prodrug P2Y12 inhibitor, could inhibit P2Y12 signaling also on VSMC. The results showed that ticagrelor was able to inhibit P2Y12 stimulated vasoconstriction, while clopidogrel had no effect. The succinate GPCR …
-
Novel Modulators of CD39 and CD73
… µM), and AG-494 (pIC50 of 4.9, IC50 of 12.6 µM). Ticagrelor M5 metabolite was determined to be a new competitive inhibitor of CD39 (pIC50 of 4, IC50 of 100 µM), displaying non-competitive inhibition kinetic patterns based on its interactions with certain residues suspected to be in the active site …
-
Economic Evaluation of a Point of Care Pharmacogenetic Test (CYP2C19) from an Ontario Perspective
… be treated with clopidogrel while prasugrel or ticagrelor could be prescribed to patients with a loss of function allele. Pharmacogenetic (PGx) testing could optimize pharmacotherapy (i.e. fewer adverse event rates with PGx option, where results are available in 1 hour) Purpose: To quantify net …
-
Investigating small-molecule inhibitors of platelet aggregation
… the nucleoside-based, reversible drug ticagrelor has been reported to cause dyspnoea due to off-target effects. Additionally, the binding modes of the P2Y12 ligands are not fully known. Interestingly, the recently solved crystal structure of P2Y12 has revealed that the orthosteric site …